Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 5/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 4/20 | 0.33 |
| ▸ | JAK3 | P52333 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15331282 | 0.90 | MAP3K5 (0.36) | IKBKETBK1L3MBTL1JAK1JAK3 | |
| SCHEMBL31747882 | 0.82 | CA1 (0.31) | — | |
| SCHEMBL671710 | 0.80 | L3MBTL1 (0.51) | KDM5BL3MBTL1 | |
| SCHEMBL11931264 | 0.79 | DUT (0.34) | — | |
| SCHEMBL15663094 | 0.78 | IKBKE (0.32) | IKBKETBK1KDM5BLRRK2RET | |
| SCHEMBL2551385 | 0.78 | KIT (0.37) | IKBKETBK1KDM5BFEN1L3MBTL1 | |
| SCHEMBL23227826 | 0.77 | L3MBTL1 (0.41) | L3MBTL1 | |
| SCHEMBL16101416 | 0.77 | IKBKE (0.38) | IKBKETBK1KDM5BFEN1LRRK2 | |
| SCHEMBL23227824 | 0.77 | MAPT (0.33) | L3MBTL1 | |
| SCHEMBL15334490 | 0.77 | L3MBTL1 (0.33) | FEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PFIZER INC. (US) | 2024-07-25 | — | — | US | disclosed |
| EP-3442974-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| CN-116063326-A | Amino-containing macrocyclic compounds as protein kinase modulators | 赛诺哈勃药业（成都）有限公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115698009-A | CD73 inhibiting 2,4-dioxopyrimidine compounds | 吉利德科学公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2970211-B1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| EP-2970211-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151106-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | IKBKE 742/4885TBK1 3303/4885KDM5B 6/4885 |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | IKBKE 742/4885TBK1 3303/4885KDM5B 6/4885 |
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PREP, PEPD, ACE | IKBKE 1368/4885TBK1 1703/4885KDM5B 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.